Colorectal cancer, which includes cancer of the colon or rectum, represents a significant paradox in modern medicine. While it is exceptionally common and highly lethal—ranking as the second leading cause of cancer-related deaths globally—it is also one of the most preventable and treatable forms of cancer when caught in its earliest stages. Addressing this challenge requires a combination of clinical expertise and a deep commitment to patient outcomes, a mission shared by experts like Dr. Umapathy Sundaram.
As a physician and medical leader with extensive experience in clinical practice, academic medicine, and health system leadership, Dr. Sundaram focuses his work on evidence-based care and translational research to improve the standard of care for patients facing this silent threat.
“The primary barrier to defeating this disease isn’t a lack of medical technology; it is a lack of awareness and timely action,” says Dr. Sundaram.
Because colorectal cancer often develops without noticeable warning signs for years, proactive testing is a critical component of preventive health. Understanding the progression of the disease, the impact of early intervention, and shifting demographics reveals why screening is a highly effective tool for improving patient outcomes.
The Silent Progression: From Polyps to Malignancy
To understand why early screening is so vital, one must understand how colon cancer develops. Unlike some aggressive cancers that materialize rapidly, colorectal cancer typically moves at a glacial pace. It almost always begins as a small, non-cancerous clump of cells on the inner lining of the colon or rectum, known as a polyp.
While there are different types of polyps, some adenomatous polyps can develop into cancer over time.
This slow timeline is a massive clinical window of opportunity. During this precancerous phase, a person will feel entirely healthy. They will not have abdominal pain, their bowel habits will be normal, and they will not see blood in their stool. If a doctor identifies and removes these polyps during a routine screening procedure, the cancer is prevented before it ever has a chance to start. In this way, screening tools like colonoscopies do not just detect cancer; they actively prevent it.
The Staging Dilemma: Survival Rates vs. Diagnostic Timing
When cancer does develop, the timing of the diagnosis dictates a patient’s medical reality, influencing everything from the intensity of their treatment to their long-term survival odds. Oncologists classify colon cancer into stages based on how deeply it has invaded the colon wall and whether it has spread to other parts of the body.
Survival rates for colorectal cancer are closely tied to the stage at diagnosis. The American Cancer Society (ACS) utilizes SEER relative survival categories to track these outcomes. According to ACS data, localized cancer (confined to the colon or rectum) has a five-year survival rate of 91%. Regional cancer (spread to nearby structures or lymph nodes) has a survival rate of 74%, while distant cancer (metastasized to organs like the liver or lungs) has a five-year survival rate of 13%.
When colon cancer is caught in the localized stage, treatment is highly successful, often requiring only localized surgery to remove the malignant segment of the bowel. Patients can frequently avoid the systemic toll of chemotherapy or radiation.
If cancer is not identified early, it can penetrate the bowel wall and spread through the lymphatic system or bloodstream. Advanced cases often require more intensive treatment regimens, which may include systemic chemotherapy, targeted biological therapies, and complex surgeries. Consequently, the clinical focus may shift from localized intervention to comprehensive disease management.
“In gastroenterology, early detection is our most effective strategy,” says Dr. Sundaram. “Identifying the disease in its localized stage significantly improves survival odds and typically allows for less invasive treatment options.”
The Dangerous Myth of Symptom-Driven Medicine
A common misconception is that a lack of symptoms indicates the absence of disease. Many colorectal cancers are asymptomatic in their early stages, making routine screening essential for those without any physical complaints.
Clinical Note: Routine screening is intended for asymptomatic individuals. If symptoms are present, a diagnostic evaluation is warranted to investigate the underlying cause.
Symptoms can occur at any stage, but early colorectal cancer often causes no symptoms. When symptoms finally break through, they typically include:
- A persistent, unexplained change in bowel habits (such as continuous diarrhea, constipation, or narrowing of the stool).
- Feeling like your bowel doesn’t empty completely.
- Rectal bleeding or dark, tarry blood mixed into the stool.
- Persistent abdominal discomfort, such as frequent gas, bloating, or cramps.
- Unexplained iron-deficiency anemia (caused by microscopic, invisible blood loss from a tumor over many months).
- Constant fatigue and sudden, unintentional weight loss.
Waiting for these signs to develop can allow the disease to progress. Screening is designed to detect changes early, often while the condition is still localized or in a preventable precancerous state.

The Shifting Landscape: Why Age 45 is the New 50
For decades, the standard medical consensus suggested that colon cancer screening should begin at age 50. This guideline was based on historical data showing that the vast majority of colorectal cancers occurred in older adults. However, the epidemiology of the disease has undergone a dramatic and alarming shift over the last two decades.
While rates of colon cancer have been steadily declining among older adults, largely due to increased screening adherence in that demographic, rates among adults under the age of 50 have been climbing sharply. Today, millennials and Gen Xers face a significantly higher risk of developing colorectal cancer than previous generations did at the same age.
In response to increasing rates of colorectal cancer in younger populations, the U.S. Preventive Services Task Force (USPSTF) and other major medical organizations updated their guidelines to recommend that average-risk individuals begin screening at age 45.
While 45 is the standard starting point for average-risk adults, the decision to screen adults aged 76 to 85 should be individualized, taking into account the patient’s overall health and prior screening history.
For individuals with a family history of colorectal cancer or certain hereditary syndromes, earlier or more frequent screening may be necessary. The specific timing and method of screening for high-risk patients depend on factors such as the type of relative affected and their age at diagnosis.
Breaking Down the Options: Screening is Easier Than You Think
Another significant barrier to early screening is fear or aversion to the procedure itself. Many people hear the word “screening” and immediately picture a colonoscopy, assuming it will be an incredibly painful, invasive, or embarrassing ordeal.
While colonoscopy is the only screening test that can examine the entire colon and remove polyps during the same procedure, it is far from the only effective option.
Common screening options include:
1. Visual/Structural Exams
- Colonoscopy (Every 10 years): A specialist uses a thin, flexible tube to examine the colon. Patients are typically sedated to ensure comfort during the procedure. While the bowel preparation is a necessary step, the procedure provides a thorough evaluation and the ability to remove polyps immediately.
- CT Colonography (Every 5 years): Also known as a virtual colonoscopy, this uses advanced X-rays to create a 3D view of the colon. It requires the same bowel prep but no sedation.
2. Non-Invasive Stool-Based Tests
- FIT (Fecal Immunochemical Test – Yearly): A highly sensitive test done in the privacy of your home that detects hidden, microscopic traces of blood in the stool, which can be an early sign of polyps or tumors.
- mt-sDNA (Multi-target Stool DNA test, e.g., Cologuard – Every 3 years): This home test looks for both hidden blood and specific altered DNA markers shed by precancerous polyps or cancer cells.
If a stool-based test comes back positive, it does not mean you definitively have cancer, but it does mean a follow-up colonoscopy should be arranged promptly to investigate the cause. The best screening test is quite simply the one that actually gets done.
The Ultimate Takeaway
Colorectal cancer screening represents a significant advancement in preventive medicine, offering a clear path to identifying and addressing a potentially serious condition before it impacts a patient’s health.
“Colon cancer is preventable when we take screening seriously,” says Dr. Sundaram. “I encourage everyone who is eligible to know when they should be screened, understand their personal and family risk factors, and not put off testing. Screening can detect precancerous changes or cancer before symptoms ever appear, when treatment is often most effective.”
Scheduling a screening at the recommended age is an important act of health maintenance. By following established clinical guidelines, individuals can significantly reduce their risk and ensure that any issues are addressed in their most treatable stages.
Screening allows for the early detection of colorectal cancer or the removal of precancerous polyps. Average-risk, asymptomatic adults should begin screening at age 45. Individuals with symptoms should seek a diagnostic evaluation. Those with a significant family history or other risk factors should consult a healthcare provider about a personalized screening plan.
Dr. Umapathy Sundaram is a physician and medical leader with extensive experience in clinical practice, academic medicine, and health system leadership. His work is dedicated to improving patient outcomes through evidence-based care, interdisciplinary collaboration, and translational research. You can learn more at umapathysundaram.com.
This content is provided for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Every individual’s health circumstances are unique; please consult with a qualified healthcare provider for personalized medical guidance.






















